Biosimilar medicine authorized by the AEMPS
ACTIVE PRINCIPLE: trastuzumab DATE: 03/08/2020 MORE INFO
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.
PRIVACY POLICY
SUBSCRIBE
